Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Next Previous
X
Search
Trial Profile

Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary) ; Tobramycin
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR-108
  • Sponsors Insmed

    • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to completed, as reported by an Insmed media release.
    • 01 Jul 2013 Top-line results reported in an Insmed media release.
    • 01 Jul 2013 Primary endpoint 'Non-inferiority of amikacin vs tobramycin in change in forced expiratory volume in 1 second' has been met, according to an Insmed media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top